Citation tools
"Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors." Journal of Nuclear Medicine
59.3
(2018):
452-458.
Web. 18 Mar. 2024.